
Global R&D Pipeline
My Favorite
Hot Targets:
IL2RA
Back
Total number of drugs
67
Phase II and later clinical stages
16.4%
Involving companies
76
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WO2023245021 | WO2023245021 | Bispecific antibody | Neoplasms | Invenra, Inc. | Invenra, Inc. | Discovery | WO2023245021 | detail > | |||||||||||||
| INO-9112 | INO-9112 | DNA vaccine Prophylactic vaccine | Infectious Diseases Digestive System Disorders Respiratory Diseases | Interleukin-2 receptor alpha chain agonists | Inovio Pharmaceuticals, Inc. | Phase 1 | INO-9112 | detail > | |||||||||||||
| AST-202 | AST-202 | Therapeutic vaccine mRNA vaccine | Neoplasms Endocrinology and Metabolic Disease Urogenital Diseases | Interleukin-2 receptor alpha chain inhibitors | Aston SCI | Preclinical | AST-202 | detail > | |||||||||||||
| Anti-interleukin-2 receptor monoclonal antibody 33B3-1(Immunotech) | Anti-interleukin-2 receptor monoclonal antibody 33B3-1(Immunotech) | Monoclonal antibody | Immune System Diseases | Interleukin-2 receptor alpha chain inhibitors | Immunotech | Discontinued | Anti-interleukin-2 receptor monoclonal antibody 33B3-1(Immunotech) | detail > | |||||||||||||
| Albumin-interleukin-2 | Albumin-interleukin-2 | Interleukins | Neoplasms | Interleukin-2 receptor alpha chain agonists | CSL Behring LLC | Discontinued | Albumin-interleukin-2 | detail > | |||||||||||||
| WO2024213046 | WO2024213046 | Antibody | Neoplasms Immune System Diseases | Suzhou Transcenta Therapeutics Co., Ltd. | Suzhou Transcenta Therapeutics Co., Ltd. | Discovery | WO2024213046 | detail > | |||||||||||||
| WO2024131023 | WO2024131023 | Nanobody | Neoplasms | Discovery | WO2024131023 | detail > | |||||||||||||||
| WO2024034759 | WO2024034759 | Radiolabeled antibody | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases | Samsung Life Public Welfare FoundationResearch & Business Foundation Sungkyunkwan University | Samsung Life Public Welfare FoundationResearch & Business Foundation Sungkyunkwan University | Discovery | WO2024034759 | detail > | |||||||||||||
| WO2024006961 | WO2024006961 | Recombinant polypeptide | Immune System Diseases Nervous System Diseases Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases | Neurogene, Inc.Neoleukin Therapeutics, Inc. | Neurogene, Inc. | Discovery | WO2024006961 | detail > | |||||||||||||
| TGI-18 | TGI-18 | Trispecific antibody | Neoplasms | Interleukin-2 receptor alpha chain inhibitors Programmed cell death protein 1 inhibitors Vascular endothelial growth factor inhibitors | Hefei TG ImmunoPharma Co., Ltd | Hefei TG ImmunoPharma Co., Ltd | Preclinical | Preclinical | TGI-18 | detail > |
Total 67 data
1
2
3
4
5
6
7


